---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Co-prescribed/Concomitant therapies"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Co-prescribed/Concomitant therapies. Topics: Immunoprophylaxis given with the vector: sirolimus and oral prednisolone, Immunosuppression initiation relative to dosing, Completion of the steroid and sirolimus tapers in the first participants treated, Adverse events attributed to the immunosuppressive regimen, and 1 further topic. 5 evidence topics quoted from 3 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/co-prescribed-concomitant-therapies"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Co-prescribed/Concomitant therapies

<a id="heading-2.1.2.12"></a>

## 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

### Immunoprophylaxis given with the vector: sirolimus and oral prednisolone

> “Immunoprophylaxis was initiated on Day –7 and administered at the study site in Montréal”
> “Sirolimus (blood trough: 4 – 8 ng/mL)”
> “Oral prednisolone.”

Source: [Rossignol et al. (2023)](https://tayshagtx.com/wp-content/uploads/Early-safety-and-efficacy-observations-following-the-first-use-of-TSHA-102-gene-therapy-in-a-patient-with-Rett-Syndrome.pdf)

<a id="topic-2.1.2.12-2"></a>

### Immunosuppression initiation relative to dosing

> “Following immunosuppression initiation at Day –7”

Source: [Rossignol et al. (2024b)](https://tayshagtx.com/wp-content/uploads/TSHA-102-gene-therapy-for-Rett-syndrome-First-cohort-data-from-the-REVEAL-Adolescent-Adult-and-Pediatric-studies.pdf)

<a id="topic-2.1.2.12-3"></a>

### Completion of the steroid and sirolimus tapers in the first participants treated

> “The first adult patient sustained improvements at week 52 post-treatment after the completion of her steroid and sirolimus taper”
> “The second adult patient showed sustained improvements following the completion of her steroid taper at week 25 post-treatment”

Source: [Taysha Gene Therapies low dose cohort data announcement (2024)](https://www.sec.gov/Archives/edgar/data/1806310/000119312524163050/d851091dex991.htm)

<a id="topic-2.1.2.12-4"></a>

### Adverse events attributed to the immunosuppressive regimen

> “The most common AE overall was vomiting (5 TEAEs), a known risk of sirolimus.”
> “Has experienced irritability thought to be secondary to immunosuppression.”

Source: [Rossignol et al. (2024b)](https://tayshagtx.com/wp-content/uploads/TSHA-102-gene-therapy-for-Rett-syndrome-First-cohort-data-from-the-REVEAL-Adolescent-Adult-and-Pediatric-studies.pdf)

<a id="topic-2.1.2.12-5"></a>

### Antiseizure medications during follow-up

> “Phenobarbital was added to regimen at Week 4 due to event of increased seizures.”
> “Stable seizure events with lower levels of anti-seizure medication, relative to Baseline”

Source: [Rossignol et al. (2024b)](https://tayshagtx.com/wp-content/uploads/TSHA-102-gene-therapy-for-Rett-syndrome-First-cohort-data-from-the-REVEAL-Adolescent-Adult-and-Pediatric-studies.pdf)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
